GeoVax Labs, Inc. (GOVX)


Stock Price Forecast

April 23, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading GeoVax Labs, Inc. chart...

About the Company

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

26

Exchange

Nasdaq

$0M

Total Revenue

26

Employees

$3M

Market Capitalization

-0.77

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GOVX News

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

20d ago, source: Yahoo Finance

ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...

GeoVax Labs, Inc. (GOVX)

4d ago, source: Yahoo Finance

Presentation Made During the 24th Annual World Vaccine CongressATLANTA, GA - (NewMediaWire) - April 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

GeoVax Labs, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details ...

GeoVax Labs gets grant for recombinant MVA vector for generating immune response to hemorrhagic viruses

6d ago, source: Pharmaceutical Technology

Discover how GeoVax Labs Inc's patented MVA vector technology targets deadly hemorrhagic fever viruses like ebolavirus and Marburgvirus, offering both preventive and therapeutic benefits.

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

26d ago, source: Stockhouse

GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials: GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor ...

GeoVax Labs Inc. Wt

1mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

GeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

19d ago, source: Finanznachrichten

ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...

Geovax Labs Inc GOVX

12d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GeoVax Labs Inc (GOVX)

20d ago, source: Investing

ATLANTA - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotech firm focused on developing vaccines for infectious diseases and cancer immunotherapies, announced at the 24th Annual World ...

GeoVax Labs, Inc. (GOVX)

1mon ago, source: Yahoo Finance

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...